Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Several ocular diseases complicated by neovascularization are being treated by repeated intraocular injections of vascular endothelial growth factor (VEGF) antagonists. While substantial benefits have been documented, there is concern that unrecognized damage may be occurring, because blockade of VEGF may damage the fenestrated vessels of the choroicapillaris and deprive retinal neurons of input from a survival factor. One report has suggested that even temporary blockade of all isoforms of VEGF‐A results in significant loss of retinal ganglion cells. In this study, we utilized double transgenic mice with doxycycline‐inducible expression of soluble VEGF receptor 1 coupled to an Fc fragment (sVEGFR1Fc), a potent antagonist of several VEGF family members, including VEGF‐A, to test the effects of VEGF blockade in the retina. Expression of sVEGFR1Fc completely blocked VEGF‐induced retinal vascular permeability and significantly suppressed the development of choroidal neovascularization at rupture sites in Bruch's membrane, but did not cause regression of established choroidal neovascularization. Mice with constant expression of sVEGFR1Fc in the retina for 7 months had normal electroretinograms and normal retinal and choroidal ultrastructure including normal fenestrations in the choroicapillaris. They also showed no significant difference from control mice in the number of ganglion cell axons in optic nerve cross sections and the retinal level of mRNA for 3 ganglion cell‐specific genes. These data indicate that constant blockade of VEGF for up to 7 months has no identifiable deleterious effects on the retina or choroid and support the use of VEGF antagonists in the treatment of retinal diseases. J. Cell. Physiol. 217: 13–22, 2008. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 3×
“…did not cause improvement and merely slowed the rate of vision loss, intraocular injections of ranibizumab, an Fab fragment that binds all isoforms of VEGF-A, caused significant improvement in 30–40% of patients that was sustained for at least 2 years (Brown et al., 2006; Rosenfeld et al., 2006).”
BackgroundVEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691 · cited 2×
“, 2003a), a recombinant protein consisting of the VEGF binding domains of VEGFR1 and VEGFR2 and an Fc domain that is an extremely potent antagonist of multiple VEGF family members (Holash et al., 2002).”
BackgroundOosthuyse, B., Moons, L., Storkebaum, E., Beck, H., Nuyens, D., Brusselmans, K., Dorpe, J. V., Hellings, P., Gorselink, M., Heymans, S., et al. (2001) · Nature Genetics · doi:10.1038/88842 · Cited by 1,007
Vascular endothelial growth factor: Direct neuroprotective effect in in vitro ischemia
Jin, K. L., Mao, X. O., & Greenberg, D. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.18.10242 · Cited by 684
Cited by
Molecular pathogenesis of retinal and choroidal vascular diseases
Campochiaro, P. A. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.06.002 · Cited by 545
Self-citationRole and Therapeutic Potential of VEGF in the Nervous System
Ruiz de Almodovar, C., Lambrechts, D., Mazzone, M., & Carmeliet, P. (2009) · Physiological Reviews · doi:10.1152/physrev.00031.2008 · Cited by 448
Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease
Tolentino, M. (2011) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2010.08.006 · Cited by 304
Preclinical safety evaluation of AAV2-sFLT01— a gene therapy for age-related macular degeneration
MacLachlan, T. K., Lukason, M., Collins, M., Munger, R., Isenberger, E., Rogers, C., Malatos, S., DuFresne, E., Morris, J., Calcedo, R., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.258 · Cited by 166
Brain homeostasis: VEGF receptor 1 and 2—two unequal brothers in mind
Wittko-Schneider, I. M., Schneider, F. T., & Plate, K. H. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1279-3 · Cited by 62
Metadata
- Authors
- Ueno, S., Pease, M. E., Wersinger, D. M. B., Masuda, T., Vinores, S. A., Licht, T., Zack, D. J., Quigley, H., Keshet, E., & Campochiaro, P. A.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2008-06-09
- Volume
- 217
- Issue
- 1
- Pages
- 13-22
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W1521544341
- Cited by
- 61
- References
- 4
- FWCI
- 6.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.